NCT05717764View on ClinicalTrials.gov

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Recurrent Metastatic Nasopharyngeal Carcinoma
Interventions
DRUG

Mitoxantrone hydrochloride liposome injection

Mitoxantrone hydrochloride liposome injection will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.

DRUG

Capecitabine

Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.

All Listed Sponsors
lead

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

INDUSTRY

NCT05717764 - Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment | Biotech Hunter | Biotech Hunter